\nIllumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection.\n<\/p>\n
\n\u201cThis acquisition is procompetitive, and we have offered far-reaching structural and behavioral remedies to address any potential concerns. Illumina will continue to work with the European Commission (EC) to ensure that it has the information and assurances necessary to approve this transaction. We look forward to presenting our position during the Phase II process,\u201d said Charles Dadswell, General Counsel for Illumina.\n<\/p>\n
\nIllumina is also challenging the EC\u2019s jurisdiction to investigate the transaction under Article 22 of the European Union (EU) Merger Regulation. The Commission reversed decades of merger policy in asserting jurisdiction under Article 22 of the EU Merger Regulation on April 19, 2021, seven months after the deal was announced<\/a>. Illumina has filed an action<\/a> in the General Court of the EU seeking annulment of the EC\u2019s jurisdiction to review the acquisition.\n<\/p>\n \n\u201cThe Commission\u2019s unprecedented decision to assert jurisdiction to review this transaction between two U.S.-based companies leaves businesses around the world uncertain as to how the EU Merger Regulation will be applied in the future,\u201d said Dadswell.\n<\/p>\n \nIllumina\u2019s re-acquisition of GRAIL means that millions of citizens across the European Economic Area (EEA) will be able to access life-saving early cancer screening years sooner. \u201cWhen people have access to early cancer detection, lives will be saved,\u201d said Francis deSouza, Chief Executive Officer of Illumina. \u201cIf this acquisition does not proceed, GRAIL\u2019s European roll-out will be slower and the cost will be measured in the unnecessary loss of life. Re-uniting GRAIL with Illumina will accelerate availability of the GRAIL test by many years in the EEA and globally, saving tens of thousands of lives, and leading to significant health care cost savings.\u201d\n<\/p>\n About Illumina<\/b><\/p>\n \nIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com<\/a> and connect with us on Twitter<\/a>, Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a>, and YouTube<\/a>.\n<\/p>\n Additional Information and Where to Find It<\/b><\/p>\n \nIn connection with the proposed transaction, Illumina, Inc. (\u201cIllumina\u201d) filed with the Securities and Exchange Commission (the \u201cSEC\u201d) a registration statement on Form S-4 (File No. 333-250941) (as amended, the \u201cRegistration Statement\u201d), which includes a prospectus with respect to Illumina\u2019s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (\u201cGRAIL\u201d) in connection with the proposed transaction (the \u201cConsent Solicitation Statement\/Prospectus\u201d). The Registration Statement was declared effective by the SEC on February 9, 2021. The Consent Solicitation Statement\/Prospectus was first distributed to GRAIL stockholders on or about February 17, 2021. On March 4, 2021, Illumina filed with the SEC Prospectus Supplement No. 1 to the Consent Solicitation Statement\/Prospectus and a registration statement on Form S-4 (File No. 333-253891) pursuant to Rule 462(b) of the Securities Act of 1933, as amended (the \u201c462(b) Registration Statement\u201d). The 462(b) Registration Statement relates to the Registration Statement and was declared effective automatically upon filing with the SEC. Illumina may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Consent Solicitation Statement\/Prospectus or the Registration Statement or any other document which Illumina may file with the SEC. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT\/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Registration Statement, which includes the Consent Solicitation Statement\/Prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC at www.sec.gov<\/a>, through Illumina\u2019s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122.\n<\/p>\n No Offer or Solicitation<\/b><\/p>\n \nThis communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.\n<\/p>\n Cautionary Notes on Forward-Looking Statements<\/b><\/p>\n \nThis communication contains \u201cforward-looking statements\u201d within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201csee,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201ctarget,\u201d similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illumina\u2019s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of Illumina\u2019s common stock and on Illumina\u2019s operating results, (vi) risks associated with third-party contracts containing consent and\/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of Illumina to integrate, GRAIL\u2019s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and Illumina\u2019s ability to develop and commercialize, GRAIL\u2019s products; (ix) the risk that disruptions from the proposed transaction will harm Illumina\u2019s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the Consent Solicitation Statement\/Prospectus that is included in the Registration Statement, as well as in Illumina\u2019s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management\u2019s response to any of the aforementioned factors.\n<\/p>\n \nThese risks, as well as other risks associated with the proposed transaction, are more fully discussed in the Consent Solicitation Statement\/Prospectus that is included in the Registration Statement. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illumina\u2019s financial condition, results of operations, credit rating or liquidity. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210722005796\/en\/<\/a><\/span><\/p>\n Investors: Media: KEYWORDS:<\/b> Europe United States North America California<\/p>\n INDUSTRY KEYWORDS:<\/b> Research Medical Devices Genetics Other Health General Health Pharmaceutical Health Science Oncology Other Science<\/p>\n<\/p>\n
\n<\/b>
Brian Blanchett
\n
858.291.6421
\n
IR@illumina.com<\/a><\/p>\n
\n<\/b>
Dr. Karen Birmingham
\n
EMEA: +44 7500 105665
\n
US: 646.355.2111
\n
kbirmingham@illumina.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210722005796\/en\/767099\/3\/illumina-logo-black%5B4%5D.jpg\"){kind=logo}
<\/td>\n<\/tr>\n